Author: Trevi Therapeutics, Inc.

Posted Date:

May 5, 2026

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc.

May 5, 2026
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Trevi Therapeutics, Inc.

April 30, 2026
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

Trevi Therapeutics, Inc.

April 28, 2026
Trevi Therapeutics to Participate in Upcoming May Events

Trevi Therapeutics, Inc.

April 23, 2026
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics, Inc.

April 20, 2026
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Trevi Therapeutics, Inc.

April 16, 2026
Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics, Inc.

April 16, 2026
Trevi Therapeutics to Participate in Upcoming Events

Trevi Therapeutics, Inc.

April 1, 2026
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc.

March 17, 2026
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Trevi Therapeutics, Inc.

March 10, 2026